Skip to main content
Log in

The Use of Pharmaceuticals in Critical Care

The Importance of Outcome Prediction Models

  • Leading Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Sonnefield ST, Waldo DR, Lemieux JA. et al. Projections of national health expenditures through the year 2000. Health Care Finane Rev 1991: 13: 1–27

    Google Scholar 

  2. Oye RD, Bellamy PE. Patterns of resources consumption in medical intensive care. Chest 1991; 99: 685–9

    Article  PubMed  CAS  Google Scholar 

  3. Wagner DP, Wineland TD, Knaus WA. The hidden cost of consumption in an intensive care unit. Health Care Finance Rev 1983; 5: 81–6

    CAS  Google Scholar 

  4. Rapoport J, Teres D, Lemeshow S, et al. Explaining variability or cost using a severity–of–illness measure for ICU patients. Med Care 1990: 28: 338–48

    Article  PubMed  CAS  Google Scholar 

  5. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985: 13: 818–29

    Article  PubMed  CAS  Google Scholar 

  6. Le Gall JR, Loirat P, Alperovitch A, et al. A simplified acute physiology score for ICU patients. Crit Care Med 1984; 12: 975–7

    Article  PubMed  Google Scholar 

  7. Teres D, Lemeshow S. Evaluating the severity of illness in critically ill patients. In: Shoemaker WE, Abraham E, editors. Diagnostic methods in critical care: automated data collection and interpretation. New York: Marcel Dekker, Inc., 1981: 1–17

    Google Scholar 

  8. Udvarhelyi IS, Colditz GA, Rai A, et al. Cost–effectiveness and cost–benefit analysis in the medical literature. Ann Intern Med 1992: 116: 238–44

    PubMed  CAS  Google Scholar 

  9. Bottman JL, Wertheimer AI, Zaske D, et al. Individualizing gentamicin dosage regimens in burn patients with gram–negative septicemia: a cost–benefit analysis. J Pharmaceutical Sci 1979: 68: 267–72

    Article  Google Scholar 

  10. Franklin C, Nightingale S, Mamdani B. A randomized comparison of nifedipine and sodium nitroprusside in severe hypertension. Chest 1986: 90: 500–3

    Article  PubMed  CAS  Google Scholar 

  11. Kreis DJ, Augestein D, Martinez O, et al. A prospective randomized study of moxalactam versus gentamicin and clindamycin in penetrating abdominal trauma. Surg Gynecol Obstet 1986: 163: 1–4

    PubMed  Google Scholar 

  12. Laffel GL, Fineberg HV, Braunwald E, A cost–effective model for coronary thrombolysis/reperfusion therapy. J Am Coll Cardiol 1987: 10 Suppl. B: 79b–9Ob

    Article  Google Scholar 

  13. Chapekis AT, Burek K, Topol EJ. The cost: benelit ratio for accute intervention for myocardial infarction: results of a prospective, matched pair analysis. Am Heart J 1989: 118: 878–82

    Article  PubMed  CAS  Google Scholar 

  14. Dunagan WC, Woodward RS, Medoff G. et al. Antimicrobial misuse in patients with positive blood cultures. Am J Med 1989; 87: 253–9

    Article  PubMed  CAS  Google Scholar 

  15. Fenn P, Gray AM, McGuire A, The cost–effectiveness of thrombolytic therapy following acute myocardial infarction. Br J Clin Pharmacol 1991: 45: 181–4

    CAS  Google Scholar 

  16. Schulman KA, Glick HA, Rubin H, et al. Cost–effectiveness of HA-1A monoclonal antibody for gram–negative sepsis. JAMA 1991; 266: 2466–71

    Article  Google Scholar 

  17. Smedstad KG, Beattie WS, Blair WS. et al. Postoperative pain relief and hospital stay after total esophagectomy. Clin J Pain 1992: 8: 149–53

    Article  PubMed  CAS  Google Scholar 

  18. Levin LA, Jansson B. Cost–effectiveness of thrombolysis–a randomized study of intravennus rt–PA in suspected myocardial infarction. Eur Heart J 1992; 13: 2–8

    PubMed  CAS  Google Scholar 

  19. Chalfin DB, Holbein EB, Fein AM, et al. Cost–effectiveness of monoclonal antibodies to Gram–negative endoxotin in the treatment of Gram–negative sepsis in ICU patients. JAMA 1993; 269: 249–54

    Article  PubMed  CAS  Google Scholar 

  20. Reeder GS, Baily KR, Gersh BJ, et al. Cost comparison of immediate angioplasty versus thrombolysis followed by conservative therapy for acute myocardial infarction: a randomized prospective trial. Mayo Clin Proc 1994: 69: 5–12

    PubMed  CAS  Google Scholar 

  21. Weinstein MC, Slawn WB, Foundations of cost–effectiveness analysis for health and medical practices. N Engl J Med 1977: 269: 116–21

    Google Scholar 

  22. AIMS Trial Study Group. Long–term effects of intravenous anistreplase in a cute myocardial infarction: final report of the AIMS study. Lancet 1990: 335: 427–31

    Google Scholar 

  23. Feller I, Tholen D, Cornell RG. Improvements in bum care 1965 to 1979. JAMA 1980; 244: 2074–8

    Article  PubMed  CAS  Google Scholar 

  24. Lemeshow S, Teres D. Avrunin JS. et al. Refining intensive care unit outcome prediction by using a changing probabilities of mortality. Crit Care Med 1988: 16: 470–7

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clifton, G.D., Blumenschein, K. The Use of Pharmaceuticals in Critical Care. Pharmacoeconomics 7, 388–392 (1995). https://doi.org/10.2165/00019053-199507050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199507050-00003

Keywords

Navigation